South Africa Urged To Revoke Key COVID-19 Patents
Lilly's Baricitinib Patent Is Claimed To Be Limiting Access To Affordable Generics
Eli Lilly’s Olumiant (baricitinib) patent in South Africa is unjustifiably preventing generics manufacturers from selling cheaper versions of the product in the country, NGO MSF insists. The arthritis drug has been recommended by the WHO as a treatment for severe and critical cases of COVID-19.
